NASDAQ · SLGL

Sol – Gel Technologies Ltd.

$81.96 +$1.41 (+1.75%) 1D Market open

Key Metrics

$263.32M
Market cap
P/E · TTM
$19.39M
Revenue · TTM
−$6.13M
Net income
EPS · TTM $-2.26
Dividend yield
Free cash flow $275.00K
Beta · 1Y 0.62
EBITDA · TTM −$7.43M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 19
    From its Mar 3 high, the share price fell 35%.

    Peak close $97.97 on Mar 3; trough close $63.31 on May 19. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -35%
  • Mar 31
    The stock moved +15.6% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 31
  • Mar 24
    The stock moved +20.9% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 24

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$263.32M
Enterprise value
Shares outstanding3.3M
52-wk range$10.77 – $97.97
Avg volume · 20D12.4K
Net cash
Book value / share$8.42
ExchangeNASDAQ
About Sol – Gel Technologies Ltd.
IPO dateFeb 1, 2018
Employees28

Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S13.58
P/FCF957.52
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating -38.9%
Net -31.6%
FCF 1.4%
ROE / ROIC -23.7% · —

Financial Health

Current ratio4.37
Quick ratio
Debt / equity
Debt / EBITDA
Net cash
Working capital$20.80M

Cash Flow · TTM

Operating CF $322.00K
Capex −$47.00K
Free cash flow $275.00K
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

4 / 9
Middling fundamentals · 4 of 9 signals passing

Altman Z-Score

11.8
Safe zone (> 2.99) · bankruptcy risk negligible

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2025-06-30 · computed by TickerWolf from SEC filings